Market Research Logo

Sedation - Pipeline Review, H2 2016

Sedation - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Sedation - Pipeline Review, H2 2016’, provides an overview of the Sedation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sedation
  • The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
  • The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sedation
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sedation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Sedation Overview
Therapeutics Development
Pipeline Products for Sedation - Overview
Sedation - Therapeutics under Development by Companies
Sedation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Sedation - Products under Development by Companies
Sedation - Companies Involved in Therapeutics Development
AstraZeneca Plc
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Nhwa Pharmaceutical Corporation Ltd.
NanoMedex Pharmaceuticals, Inc.
Paion AG
Primex Pharmaceuticals Oy
The Medicines Company
Therakind Limited
Sedation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABP-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADV-6209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol microemulsion - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy
Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan
Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials
Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sedation, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Sedation - Pipeline by AstraZeneca Plc, H2 2016
Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2016
Sedation - Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016
Sedation - Pipeline by Paion AG, H2 2016
Sedation - Pipeline by Primex Pharmaceuticals Oy, H2 2016
Sedation - Pipeline by The Medicines Company, H2 2016
Sedation - Pipeline by Therakind Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Sedation - Dormant Projects, H2 2016
Sedation - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Sedation, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report